Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 8, 2012. The report announces the financial and operating results for the fiscal year ended December 31, 2011. The company is incorporated in Delaware and maintains its principal executive offices in Annapolis, Maryland.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. It serves solely as a notification that the annual results have been issued.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It notes that the information in this report, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated March 8, 2012), as they are not present in the 8-K body.
- Confirm the company name is PharmAthene, Inc., as the request metadata incorrectly listed Altimmune, Inc.
- Review the full press release for any operational updates or clinical trial milestones associated with the 2011 fiscal year.